Hepatitis A – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hepatitis A – Pipeline Review, H2 2016’, provides an overview of the Hepatitis A pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis A and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatitis A

The report reviews pipeline therapeutics for Hepatitis A by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hepatitis A therapeutics and enlists all their major and minor projects

The report assesses Hepatitis A therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hepatitis A

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hepatitis A

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatitis A pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co., Ltd

Indian Immunologicals Limited

Sinovac Biotech Ltd.

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hepatitis A Overview 6

Therapeutics Development 7

Pipeline Products for Hepatitis A - Overview 7

Pipeline Products for Hepatitis A - Comparative Analysis 8

Hepatitis A - Therapeutics under Development by Companies 9

Hepatitis A - Therapeutics under Investigation by Universities/Institutes 10

Hepatitis A - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Unknown Stage Products 13

Hepatitis A - Products under Development by Companies 14

Hepatitis A - Products under Investigation by Universities/Institutes 15

Hepatitis A - Companies Involved in Therapeutics Development 16

Beijing Minhai Biotechnology Co., Ltd 16

Indian Immunologicals Limited 17

Sinovac Biotech Ltd. 18

Zydus Cadila Healthcare Limited 19

Hepatitis A - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Combination Products 21

Assessment by Target 22

Assessment by Molecule Type 23

Drug Profiles 25

(hepatitis A + hepatitis B + hepatitis E) vaccine - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

(hepatitis A + hepatitis B) vaccine - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

hepatitis A + hepatitis B vaccine - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

hepatitis A vaccine - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

hepatitis A vaccine - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

hepatitis A vaccine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

hepatitis A vaccine - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Hepatitis A - Dormant Projects 32

Appendix 33

Methodology 33

Coverage 33

Secondary Research 33

Primary Research 33

Expert Panel Validation 33

Contact Us 33

Disclaimer 34

List of Tables

List of Tables

Number of Products under Development for Hepatitis A, H2 2016 7

Number of Products under Development for Hepatitis A – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Comparative Analysis by Unknown Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Hepatitis A – Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 16

Hepatitis A – Pipeline by Indian Immunologicals Limited, H2 2016 17

Hepatitis A – Pipeline by Sinovac Biotech Ltd., H2 2016 18

Hepatitis A – Pipeline by Zydus Cadila Healthcare Limited, H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Assessment by Combination Products, H2 2016 21

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

Hepatitis A – Dormant Projects, H2 2016 32

List of Figures

List of Figures

Number of Products under Development for Hepatitis A, H2 2016 7

Number of Products under Development for Hepatitis A – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 20

Assessment by Combination Products, H2 2016 21

Number of Products by Molecule Types, H2 2016 23

Number of Products by Stage and Molecule Types, H2 2016 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports